Lupin moves up on getting USFDA's approval for Phytonadione Injectable Emulsion
Lupin is currently trading at Rs. 1953.60, up by 11.60 points or 0.60% from its previous closing of Rs. 1942.00 on the BSE.
The scrip opened at Rs. 1944.55 and has touched a high and low of Rs. 1965.50 and Rs. 1,942.00 respectively. So far 1935 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2530.00 on 16-Jul-2026 and a 52 week low of Rs. 1900.30 on 28-Oct-2025.
Last one week high and low of the scrip stood at Rs. 2035.00 and Rs. 1940.00 respectively. The current market cap of the company is Rs. 89354.46 crore.
The promoters holding in the company stood at 46.85%, while Institutions and Non-Institutions held 47.07% and 6.08% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-dose Prefilled Syringe.
The USFDA has approved Lupin’s Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-dose Prefilled Syringe as bioequivalent to the reference listed drug (RLD), Phytonadione Injectable Emulsion, 1 mg/0.5 mL, of International Medication Systems, Limited and is indicated for the treatment and prophylaxis of hypoprothrombinemia (low blood clotting) and vitamin K-deficiency.
Phytonadione Injectable Emulsion had estimated annual sales of $52.3 million in the U.S. (IQVIA MAT Aug 2026).
